IDEAYA Biosciences (IDYA) Reports Q3 Results; Issues Business Update

Go back to IDEAYA Biosciences (IDYA) Reports Q3 Results; Issues Business Update

IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 15, 2021 6:01 AM EST

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2021.

"Early clinical data on our potential best-in-class Phase 1 MAT2A inhibitor, IDE397, in... More